FlexiCath

FlexiCath, a medical device company established in 2004, operates with dual headquarters in Pittsburgh, PA, and Tel Aviv, Israel. The company was co-founded by serial entrepreneurs Shai Amisar, who serves as CEO, and Ronen Radomski, the company's CTO. Their venture began in the Misgav Technology Center, an Israeli incubator program, and secured initial funding from the Office of the Chief Scientist and Trendlines Israel Fund before attracting further investment. The company's primary focus is developing and marketing sterile catheter insertion systems designed to address challenges in midterm intravenous (IV) catheterization, which involves indwelling times of up to 29 days.

The company's flagship product is the M/29® Midterm® Catheter System, an FDA-cleared device. This system is engineered to provide a touch-free insertion process, significantly reducing the risk of airborne and touch-borne contamination, which are primary causes of catheter-related bloodstream infections. A key feature of the M/29® is its design that allows for placement in under 10 minutes with minimal training, offering the simplicity associated with short peripheral IVs but with the extended dwell time of a midline catheter. The product incorporates a sterile silicone sleeve that encloses the catheter, a Peelguard® stabilizer to prevent vessel trauma, and a specialized filter, all of which ensure the catheter remains sterile throughout the insertion procedure without requiring a maximum barrier sterile field. This polyurethane catheter is also pressure rated for contrast agent administration, expanding its clinical applications.

FlexiCath's business model centers on selling these advanced catheter systems to healthcare providers. The company targets a substantial market, with millions of IV procedures performed annually where an intermediate-term catheter presents a more efficient and safer alternative to multiple insertions of short-term cannulas. By simplifying the insertion process and reducing contamination risks, FlexiCath aims to offer a cost-effective solution that improves patient care and safety. The company has secured a total of $3.6 million in funding over two Series A rounds, with The Zitelman Group being a key institutional investor.

Keywords: midterm catheter, intravenous catheterization, sterile insertion system, medical device, catheter-related bloodstream infection, touch-free catheter, midline catheter, vascular access, polyurethane catheter, FDA cleared medical device, infusion therapy, patient safety, infection control, single-use medical device, IV therapy, sterile packaging, healthcare technology, indwelling catheter, peripheral IV, medical supplies, Shai Amisar, Ronen Radomski